195 related articles for article (PubMed ID: 6668097)
21. Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome.
Takamura N; Maruyama T; Chosa E; Kawai K; Tsutsumi Y; Uryu Y; Yamasaki K; Deguchi T; Otagiri M
Drug Metab Dispos; 2005 Apr; 33(4):596-602. PubMed ID: 15640375
[TBL] [Abstract][Full Text] [Related]
22. Furosemide disposition in cirrhotic patients.
Sawhney VK; Gregory PB; Swezey SE; Blaschke TF
Gastroenterology; 1981 Dec; 81(6):1012-6. PubMed ID: 7286579
[TBL] [Abstract][Full Text] [Related]
23. Effect of cimetidine on the absorption and efficacy of orally administered furosemide.
Rogers HJ; Morrison P; House FR; Bradbrook ID
Int J Clin Pharmacol Ther Toxicol; 1982 Jan; 20(1):8-11. PubMed ID: 7056605
[TBL] [Abstract][Full Text] [Related]
24. Determinants of furosemide delivery to its site of action.
Sjöström PA; Kron BG; Odlind BG
Clin Nephrol; 1995 Jan; 43 Suppl 1():S38-41. PubMed ID: 7781204
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of furosemide in patients on peritoneal dialysis.
Flinn A; Ledger S; Blake P
CANNT J; 2006; 16(3):40-4. PubMed ID: 17061696
[TBL] [Abstract][Full Text] [Related]
26. Defect in urinary acidification in nephrotic syndrome and its correction by furosemide.
Rodriguez-Soriano J; Vallo A; Castillo G; Oliveros R
Nephron; 1982; 32(4):308-13. PubMed ID: 7167208
[TBL] [Abstract][Full Text] [Related]
27. Vascular endothelial growth factor in children with nephrotic syndrome treated with cyclosporine A.
Wasilewska A; Zoch-Zwierz W; Tenderenda E
Acta Paediatr; 2006 Mar; 95(3):291-6. PubMed ID: 16497638
[TBL] [Abstract][Full Text] [Related]
28. [Relation between the diuretic effect of furosemide, its rate of urinary excretion, urinary concentration and the amount excreted in the urine in children with normal renal function].
Prandota J
Pediatr Pol; 1982; 57(9):703-10. PubMed ID: 7170149
[No Abstract] [Full Text] [Related]
29. Furosemide kinetics and dynamics in patients with cirrhosis.
Villeneuve JP; Verbeeck RK; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1986 Jul; 40(1):14-20. PubMed ID: 3720175
[TBL] [Abstract][Full Text] [Related]
30. Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia.
Rane A; Villeneuve JP; Stone WJ; Nies AS; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1978 Aug; 24(2):199-207. PubMed ID: 679597
[No Abstract] [Full Text] [Related]
31. [Comparison of the therapeutic efficacy of spironolactone and furosemide in patients with severe congestive heart failure].
Bednarz B; Cybulski J; Chamiec T
Pol Merkur Lekarski; 2000 Aug; 9(50):519-21. PubMed ID: 11081314
[TBL] [Abstract][Full Text] [Related]
32. Encephalopathy after furosemide use in nephrotic syndrome.
Sharma AP; Grimmer J
J Paediatr Child Health; 2007 Mar; 43(3):188-90. PubMed ID: 17316196
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and dynamics of furosemide in the newborn piglet.
Miceli JJ; Kramer PA; Chapron DJ; Rosenkrantz TS; Raye JR
J Pharmacol Exp Ther; 1990 Jun; 253(3):1126-32. PubMed ID: 2359020
[TBL] [Abstract][Full Text] [Related]
34. Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats.
Medeiros M; Pérez-Urizar J; Pedraza-Chaverri J; Muñoz-Arizpe R; Castañeda-Hernández G
Can J Physiol Pharmacol; 2007 May; 85(5):502-6. PubMed ID: 17632584
[TBL] [Abstract][Full Text] [Related]
35. [Atrial natriuretic peptide in children with nephrotic syndrome].
Jovanovitsh O; Popovitsh-Rolovitsh M; Radoshevitsh P; Stankovitsh R; Dujitsh A; Gajitsh M; Peco-Antitsh A; Krushchitsh D; Kostitsh M
Srp Arh Celok Lek; 1995; 123(11-12):291-4. PubMed ID: 16296241
[TBL] [Abstract][Full Text] [Related]
36. Saturable first-pass kinetics, plasma protein binding, and the furosemide intricacies.
Keller F
Clin Nephrol; 1995 Jan; 43 Suppl 1():S24-6. PubMed ID: 7781201
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of furosemide in advanced renal failure.
Huang CM; Atkinson AJ; Levin M; Levin NW; Quintanilla A
Clin Pharmacol Ther; 1974 Oct; 16(4):659-66. PubMed ID: 4422027
[No Abstract] [Full Text] [Related]
38. Dose-dependent pharmacokinetics of furosemide in the rat.
Hammarlund MM; Paalzow LK
Biopharm Drug Dispos; 1982; 3(4):345-59. PubMed ID: 7159689
[TBL] [Abstract][Full Text] [Related]
39. Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of furosemide.
Lee MG; Li T; Chiou WL
Biopharm Drug Dispos; 1986; 7(6):537-47. PubMed ID: 3828484
[TBL] [Abstract][Full Text] [Related]
40. The comparison of the diuretic and natriuretic efficacy of continuous and bolus intravenous furosemide in patients with chronic kidney disease.
Sanjay S; Annigeri RA; Seshadri R; Rao BS; Prakash KC; Mani MK
Nephrology (Carlton); 2008 Jun; 13(3):247-50. PubMed ID: 18315706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
